Guys, I have followed VASO closely for years, and have been long quite a bit of that time. For one thing, as I said before, this is an oft-used tactic by VASO management (which, by the way, is, or has been, definitely on the shady side). They announce "news" that really isn't news at all.
VASO's EECP has been approved for treatment of angina for several years. The article cited by management really didn't promise much beyond what they already have. Recently, the Feds cut the reimbursement rates, and the company was already struggling before that. Their great hope is that they will be approved for treatment of CHF (congestive heart failure), but that won't be for over a year, at best. In the meantime, their competition, both in EECP, as well as drugs and stents, is moving rapidly ahead.
Go ahead and play the giddy reaction to this "news"; I'm sure you can make money on it. I'm just interjecting a note about the company's real situation...
Market Data 
Markets 
AI
